Patent Update: Neurokinin Receptor Antagonists

References to primary literature

• WATLING KW: Nonpeptide antagonists her-ald new era in tachykinin research. TIPS (1992) 13:265–269.
   Web of Science ®Google Scholar
• MAGGIC A, PATACCHINRI, ROVEROP, GIACHETZ A: Tachykinin receptors and tachykinin receptor antagonists. J. Auton. Pharmucol.(1993) 13:23–93.
   PubMedGoogle Scholar
• MAGGI CA, PATACCHINI R, ROVER° P, GIULIANI S, GIACHETTI A: Tachykinin receptor an-tagonists and potential ciinicai appfications at the peripheral level. Biochem. Sac. Trans. (1991) 19:909–912.
   PubMed Web of Science ®Google Scholar
• REGOLI D, NANTEL F, TOUSIGNANT C, JUKIC D, Roulssi N, RHALEB N-E, TELEMAQUE S, DRAPEAU G, D'ORLEANs-JUSTE P: Neuro-kinin agonists and antagonists. Ann. N. Y. Acad.Sci (1991) 632:170–183.
   PubMedGoogle Scholar
• GARRET C, CARRUETTE A, FARDIN V, MOUSSAOUI S. PEYRONEL JF, BLANCHARD J-C, LADURON PM: Pharmacological properties of a potent and selective nonpeptide substance P antagonist. Proc. Natl. Acad. Sci. USA (1991) 88: 10208–10212.
   PubMed Web of Science ®Google Scholar
• LEI Y-H, BARNES PJ, ROGERS DF: Inhibition of neurogenic plasma extravasation in guinea-pig airways by CP-96,345, a non-peptide NKi receptor antagonist. Br J. Pharmacol. (1992) 105:261–262.
   PubMed Web of Science ®Google Scholar
• ADVENIER C, EMONDS-ALT X, VILAIN P, GOULAOUIC P, PROIETTO V, VAN BROECK D, NALINE E, NELIAT G, LE FUR G, BRELIERE JC: SR 48968, a potent and selective non-peptide antagonist of the neurokinin A (NK2) recep-tor. Br. J. Pharmacol. (1992) 105(Suppl):77P.
   Google Scholar
• MCELROY AB, CLEGG SP, DEAL MJ, EWAN GB, HAGAN RNI, IRELAND SJ, JORDAN CC, PORTER B, Ross BC, WARD P, WiirrriNGToN AR: Highly potent and selective heptapep-tide antagonists of the neurokinin NK-2 re-ceptor. J. Med. Chem. (1992) 35:2582–2591.
   PubMed Web of Science ®Google Scholar
• PONCELET M, GUEUDET C, EMONDS-ALT X, BRELIERE J-C, LE FUR G, SOUBRIE P: Turning behaviour induced in mice by a neurokinin A receptor agonist: stereoselective blockade by SR 48968, a non-peptide receptor antag-onist. Neuroscience Lett. (1993) 149:40–42.
   PubMed Web of Science ®Google Scholar
• FOLKERS K, HORIG J, ROSELL S, BJORKROTH U: Chemical design of antagonists of sub-stance P. Acta Physiol. Scand. (1981) 11:505–506.
   Google Scholar
• FOLICERSK, HORIGJ, RAMPOLDG, LANE P, ROSELLS, BJORKROTHU : Design and synthesis of effective antagonists of substance PActa Chem. Scand. Ser B (1982) B36:389–395.
   Google Scholar
• ESCHER E, PARENT P, MIZRAHI J, D' ORLEANS-JUSTE P, DION S, DRAPEAU G, REGOLI D: Syn-thesis and structure activity studies on no-vel SP-antagonists, an exercise in medicinal chemistry. In: Tachykinin Antagonists Halcan-son R, Sundler F (Eds) Elsevier Amsterdam, pp267–276.
   Google Scholar
• FOLKERKS, HAKANSONR, HORIG J, XU JC, LEANDER S: Biological evaluation of substance P antagonists. BE J. Pharmacol. (1984) 83:449–456.
   PubMed Web of Science ®Google Scholar
• ZHANGL, MANTEY S, JEYNSENR T, GARDNER ID: An analogue of substance P with broad receptor antagonist activity. Biochim. Biophys. Acta (1988) 972:37–44.
   PubMedGoogle Scholar
• FOLKERKS, FENG DM, ASANON, HAKANSON R, WEISENFELD-HALLZIN, LEANDERS : Spantide I1 an effective tachykinin antagonist having high potency and negligible neurotoxicity. Proc. Natl. Acad. Sci. USA (1990) 87:4833–4835.
   PubMed Web of Science ®Google Scholar
• SAK1URADA T, MANOME Y, TAN-No K, SAKUR-ADA S, OHBA M, KISARA K: Selective antago-nistic effects of substance P (6-11) analogues on the spinally induced, neurokinin 1 recep-tor mediated behavioural response. Jpn. J. Pharmacol. (1991) 55(S1):358P
   Google Scholar
• SAKURADA T, MANOME Y, TAN-No K, SAKU-RADA S, ICBARA K, OHBA M, TERENIUS L: A selective and extremely potent antagonist of the neurokinin-1 receptor. Brain Res. (1992) 593:319–322.
   PubMed Web of Science ®Google Scholar
• HAGIWARA D, MIYAKE H, MORIMOTO H, MURAI M, Fwn T, MATSUO M: Studies on neurokinin antagonists. 1. The design of no-vel tripeptides possessing the glutaminyl-D-tryptophylphenylalanine sequence as substance P antagonists. J. Med. Chem. (1992) 35:2015–2025.
   Google Scholar
• HAGIWARA D, MIYAKE H, MORIMOTO H, MURAI M, FUJII T, MATSUO M: Studies on neurokinin antagonists. 2. Design and structure-activity relationships of novel tripep-tide substance P antagonists, N-[N-(N-acetyl-L-threonyl)-N1-formyl-D-tryptophyl]-Nmethyl-N-(phenylmethy1)-L-phenylalaninamide and its related compounds. J. Med. Chem. (1992) 35:3184–3191.
   Google Scholar
• MORIMOTO H, YAMASHITA M, MATSUDA A, MIYAKEH, F u ~ nT Effects of FR 113680 and FK 224, novel tachykinin receptor antagonists, on cigarette smoke-induced rat tracheal plasma extravasation. Eur. J. Pharma-col. (1992) 224:1–5.
   PubMed Web of Science ®Google Scholar
• Jumc D, Routsst N, LAPRISE R, BOUSSOUGOU M, REGOLI D: Neurokinin receptor antago-nists old and new. Life Sci. (1991) 49:1463–1469.
   PubMedGoogle Scholar
• Routsst N, GII"IhR BD, HOWBERT JJ, Jumc D, REGOLI D: Pharmacological characteri-sation of new neurokinin (substance P) antagonists. Pharmacologist (1991) 33(3): 144.
   Google Scholar
• APPELL KC, FRAGALE BJ, LOSCIG, J, SINGH S, TOMCZUK BE: Antagonists that demon-strate species differences in neurokinin-1 re-ceptors. MoL Pharmacol. (1992) 41:772–778.
   PubMed Web of Science ®Google Scholar
• WILLIAMS BJ,CuRTis NR, MCKNIGHT AT, MAGUIRE JJ, YOUNG SC, VEBER DF, BAKER R: Cyclic peptides as selective tachykinin an-tagonists. J. Med. Chem. (1993) 36:2–10.
   PubMed Web of Science ®Google Scholar
• WARD P, EWAN GB, JORDAN CC, IRELAND SJ, HAGAN RM, BROWN JR: Potent and highly selective neurokinin antagonists. J. Med. Chem. (1990) 33:1848–1851.
   PubMed Web of Science ®Google Scholar
• HAGAN RM, IRELAND SJ, BAILEY F, MCBRIDE C, JORDAN CC, WARD P: A spirolactam conformationally-constrained analogue of physalaemin which is a peptidase-resistant, selective neurokinin receptor antagonist. Br J. Pharmacol. (1991) 102(Suppl):168P.
   Google Scholar
• LECCI A, GIULIANI S, MAGGI CA: Effect of the NK-1 receptor antagonist GR 82,334 on reflexly-induced bladder contractions. Life Sci. (1992) 51:277–280.
   Web of Science ®Google Scholar
• BERESFORD IJM, BIRCH Pj, BALSAT M-C, ROGERS H, FERNANDEZ L, HAGAN RM: Ef-fect of the spirolactam NK-1 receptor antag-onist, GR82334, on neurokinin- and electri-cal stimulation-induced oedema in the rat. Br. J. Pharmacol. (1991) 102 (S uppl): 360P.
   Google Scholar
• HASHIMOTO M, HAYASHI K, MURAI M, FUJII T, NASHIKAWA M, KNOT° S, OKUHARA M, KOHSAKA M, IMANAKA H: WS9326A, A novel tachykinin antagonist isolated from Strep-tomyces violaceusnigers No. 9326. II. Bio-logical and pharmacological properties of WS9326A and tetrahydro-WS9326A (F1(224). J. Antibiotics (1992) 45(7): 1064–1070.
   Google Scholar
• MORIMOTO H, MURAI M, MAEDA Y, YAMAOKA M, NISHIKAWA M, KIYOTOH S, FUJI' T: FK 224, A novel cyclopeptide substance P an-tagonist with NK-1 and NK-2 receptor se-lectivity. J. Pharmacol. Exp. Ther (1992) 262(1):398–402.
   PubMed Web of Science ®Google Scholar
• TASAKA K: FK-224; Neurokinin Antagonist. Drugs of the Future (1992) 17(8):679–682.
   Google Scholar
• HAYASHI K, HASHIMOTO M, SHIGEMATSU N, NISHIKAWA M, EZAKI M, YAMASHITA M, KPIOTO S, OKUHARA M, KOHSAICA M, IMANAKA H: WS9326A, A novel tachykinin antagonist isolated from Streptomyces vio-laceusnigers No. 9326. I. Taxonomy, fermen-tation, isolation, physico-chemical properties and biological activities. J. Antibiotics (1992) 45(7): 1055–1063.
   Google Scholar
• SMITH PW, MCELROY AB, PRITCHARD JM, DEAL MJ, EWAN GB, HAGAN RM, IRELAND SJ, BALL D, BERESFORD I, SHELDRICK R, JORDAN CC, WARD P: Low molecular weight neurokinin NK2 antagonists. Bioorganic & Medicinal Chemistry Reviews (1993) 3(5):931–936.
   Web of Science ®Google Scholar
• Xu X-J, DALSGAARD C-J, MAGGI CA, WEISEN-FELD-HALLIN Z: NK-1, but not NK-2, tachy-kinin receptors mediate plasma extravasa-fion induced by antidromic C-fiber stimula-tion in rat hindpaw: demonstrated with the NK-1 antagonist CP-96,345 and the NK-2 antagonist Men 10207. Neuroscience Letters (1992) 139:249–252.
   PubMed Web of Science ®Google Scholar
• ROVER° P, ASTOLFI M, RENZETTI AR, PATA-CCHIM R, GIACHETTI A, MAGGI CA: Role of D-tryptophan for affinity of MEN 10207 tachykinin antagonist at NK-2 receptors. Peptides (1991) 12:1015–1018.
   PubMed Web of Science ®Google Scholar
• ROVERO P, QUARTARA L, ASTOLFI M, PATA-CCHINI R, GIACHETTI A, MAGGI CA: Structure-activity study of the C-terminal of MEN10207 tachykinin antagonist. Peptides (1992) 13:207–208.
   PubMed Web of Science ®Google Scholar
• BUCK SH, FANGER BO, VAN GIERSBERGEN PLM: Pharmacological and biochemical evidence for multiple types of tachykinin NK2 receptors. Ann. N. E Acad. Sci. (1991) 632:112–115.
   PubMed Web of Science ®Google Scholar
• MAGGI CA, PATACCHINI R, GUILIANI S, ROVERO P, DION S, REGOLI D,AcHErn A, MELI A: Competitive antagonists discrimi-nate between NK2 tachykinin receptor sub-types. (1990) 100:591.
   Google Scholar
• ROVERO P, ASTOLFI M, MANZINI S, JUDIC D, Rouissi N, MAGGI CA, REGOLI D: Structure-activity relationship of R396, an NK2 tachy-kinin antagonist selective for the NK2B re-ceptor subtype. Neuropeptides (1992) 23:43–145.
   Web of Science ®Google Scholar
• WILLIAMS BJ, CuKris NR, McKNIGHT AT, MAGUIRE J, FOSTER A, TRIDGETT R: Devel-opment of NK-2 selective antagonists. Re gut. Pept. (1988) 22:189.
   Google Scholar
• DELAY-GOYET P, LUNDBERG JM: Dactino-mycin is a competitive neurokinin-2 receptor antagonist. Biochem. Biophys. Res. Commun. (1991) 180(3):1342–1349.
   PubMed Web of Science ®Google Scholar
• HARBESON SL, SHAILLR SA, LE T-B, BUCK SH: A new class of high affinity figands for the neurokinin A NK2 receptor: yr(CH2NR) reduced peptide bond analogues of neuro-kinin A410. J. Med. Chem. (1992) 35:3949–3955.
   PubMed Web of Science ®Google Scholar
• LOGAN ME, GOSWAMI R, TomczuK BE, VENEPALLI BR: Recent advances in neuro-kinin receptor antagonists. Ann. Rep. Med. Chem. (1991) 26:43–51.
   Web of Science ®Google Scholar
• LOWE JA, DROZDA SE, SNIDER RI, LONGO KP,ZORN SH, MORRONE J, JACKSON ER, MCLEAN S. BRYCE DK, BORDNER J, NAGAHISA A, YOSHIHITO K, SUGA O, TSUCHIYA M: The dis-covery of (2S,3S)-cis-2-(diphenylmethyD-N-[(2-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]-octan-3-amine as a novel, nonpeptide sub-stance P antagonist. J. Med. Chem. (1992) 35:2591–2600.
   Google Scholar
• SNIDER RM, CONSTANTINE JW, LOWE JA, LONGO KP, LEBEL WS, WOODY HA, DROZDA SE, DESAI MC, V1NICK FJ, SPENCER RW, HESS H-J: A potent non-peptide antagonist of the substance P NKi receptor. Science (1991) 251:435–437.
   PubMed Web of Science ®Google Scholar
• MCLEAN S, GANONG AH, SEEGER TF, BRYCE DK, PRATT KG, REYNOLDS LS, SIOK CJ, LOWE JA, HEYM J: Activity and distribution of binding sites in the brain of a nonpeptide substance P (MCI) receptor antagonist. Sci-ence (1991) 251:437–439.
   PubMed Web of Science ®Google Scholar
• SNIDER RM, LONGO 10, DROZDA SE, LOWE JA, LEEMAN SE: Effect of CP-96,345, a non-peptide substance P receptor antagonist, on salivation in rats. Proc. Natl. Acad. Sci. USA (1991) 88:10042–10044.
   PubMed Web of Science ®Google Scholar
• BERSESFORD IJM, BIRCH PJ, HAGAN RM, IRELAND SJ: Investigation into species vari-ants in tachykinin NK-1 receptors by use of the non-peptide antagonist, CP-96,345. Br J. Pharmacol. (1991) 104:292–293.
   PubMed Web of Science ®Google Scholar
• FARDIN V, FOUCAULT F, Boo( MD, GARRET C: Binding profile of RP 67580, a new non-peptide substance P antagonist: compari-son with CP-96,345. Br. J. Pharmacol (1992) 105:80P.
   Google Scholar
• BARR AJ, WATSON SP: Non-peptide antago-nists, CP-96,345 and RP 67580, distinguish species variants in tachykinin NK-1 recep-tors. Br J. Pharmacol. (1993) 108:223–227.
   PubMed Web of Science ®Google Scholar
• FONG TM, Yu H, STRADER CD: Molec-ular basis for the species selectivity of the neurokinin-1 receptor antagonists CP-96,345 and RP67580. J.Biol.Chem. (1992) 267(36):25668–25671.
   PubMed Web of Science ®Google Scholar
• EMONDS-ALT X, DOUTREMEPUICH JD, JUNG, M, PROIOEITO E, SANTUCCI V, VAN BROECK D, VILAEN P, SOUBRIE P, LE FUR G, BRELIERE JC: SR 140333, A non-peptide antagonist of substance P (N1(1) receptor.;
   Google Scholar
• JUNG M, PONCELET M, EMONDS-ALT X, LE FUR G, SOUBRIE P: Neuropharmacological profile of SR 140333, a non-peptide antagonist of substance P (NK1) receptor.;
   Google Scholar
• OURY-DONAT F, LEFEVRE IA, EMONDS-ALT X, LE FUR G, SOUBRIE P: SR 140333, A novel characterisation on the U373MG cell line. Neuropeptides (1993) 24:231–239.
   Google Scholar
• VENEPALLI BR, AIMONE LD, APPELL KC, BELL MR, DORITY JA, GOSWAMI R, HALL PL, KUMAR V, LAWRENCE KB, LOGAN ME, SCENSNY PM, SEELYE JA, TOMCZUK BE, YANNI JM: Synthesis and substance P receptor activity of androstano[3,2-b]pyrimido[ 112-a]benzimidazoles. J. Med. Chem. (1992) 35374–378.
   Web of Science ®Google Scholar
• APPELL KC, BABB BE, GOSWAMI R, HALL PL, LAWRENCE KB, LOGAN ME, PRZYKLEK-PRZYKLEKELLINGR, TOMCZUKB E, VENEPALLBI R, YANNI JM: Imidazo[4,5-b]quinoxaline cyanines as neurokinin antagonists. J. Med. Chem. (1991) 34:1751–1753.
   PubMed Web of Science ®Google Scholar
• EMONDS-ALT X, VILAIN P. GOULAOUIC P. PROIETTO V, VAN BROECK D, ADVENIER C, NALINE E, NELIAT G, LE FUR G, BRELIERE JC: A potent and selective non-peptide antago-nist of the neurokinin A (NK2) receptor. Life Sci. (1992) 50:PL101-PL106.
   Google Scholar
• ADVENIER C, NALINE E, TOTY L, BAKDACH H, EMONDS-ALT X, VILAIN P, BRELIERE J-C, LE FUR G: Effects on the isolated human bronchus of SR 48968, a potent and selective nonpeptide antagonist of the neurokinin A (NK2) receptors. Am. Rev. Respir Dis. (1992) 146(5):1177–1181.
   PubMedGoogle Scholar
• ADVENIER C, ROLTISSI N, NGUYEN QT, EMONDS-ALT X, BRELIERE J-C, NELIAT G, NALINE E, REGOLI D: Neurokinin A (NK2) receptor re-visited with SR 48968, a potent non-peptide antagonist. Biochem. Biophys. Res. Commun. (1992) 184(3):1418–1424.
   PubMed Web of Science ®Google Scholar
• CHRETTEN L, TOUSIGNANT C, GUILLEMEI lb G,REGOLI D: Non-peptide angiotensin antago-nists bind to NK-3 neurokinin receptors of rat and guinea-pig brain. Faseb J. (1993) 7(4):A710.
   Web of Science ®Google Scholar